Portfolio

Drug candidates for autoimmune diseases

Cyxone develops novel immunomodulating pharmaceutical products that may considerably improve the quality of life for patients with autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company focuses on the development of substances that inhibit key processes in the body’s cells that are typical for severe autoimmune diseases and continues to develop the company’s strategy to maximize the opportunities within autoimmune diseases.

The company’s development portfolio comprises Rabeximod in a clinical phase II program for RA and T20K that soon will enter clinical phase I for MS. In future, Cyxone will also use its cyclotide technology to develop new structures that may be beneficial for patients within other disease areas.

Development program

The company was founded in 2015 to further develop cyclotide technology in order to investigate its effect on severe autoimmune diseases. In 2016, a preclinical program was initiated for the company’s drug candidate within multiple sclerosis (MS), T20K, which has proven a positive effect and safety profile. Already the following year, in 2017, the portfolio was extended with the clinical candidate Rabeximod, which has proven effective on RA in over 200 patients. A phase IIb study is planned to begin during the second half of 2018.